Clinical Data Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug PharmaphorumBiogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.NeuroscienceRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) Pharmaphorum Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: REGENXBIO slumps after serious side effects mar Duchenne gene therapy resultsNext: ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
